Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
September 02 2022 - 6:00AM
Genetron Holdings Limited (“
Genetron Health” or
the “
Company”, NASDAQ: GTH), a leading precision
oncology platform company in China that specializes in offering
molecular profiling tests, early cancer screening products and
companion diagnostics development, announced today that the special
committee (the “
Special Committee”) of the
Company’s Board of Directors (the “
Board”) has
retained Kroll, LLC (operating through its Duff & Phelps
Opinions Practice) as its independent financial advisor and Davis
Polk & Wardwell LLP as its independent legal counsel. The
Special Committee was formed to evaluate and consider the
previously announced preliminary non-binding acquisition proposal
letter dated August 21, 2022 (the “
Proposal”) as
well as other potential strategic alternatives that the Company may
pursue.
The Board cautions the Company's shareholders and others
considering trading the Company's securities that no decisions have
been made with respect to the Proposal or any alternative strategic
option that the Company may pursue. There can be no assurance that
any definitive offer will be received, that any definitive
agreement will be executed relating to the transaction contemplated
by the Proposal or that any other transaction will be approved or
consummated. The Company does not undertake any obligation to
provide any updates with respect to any transaction, except as
required under applicable law.
About Genetron Holdings
LimitedGenetron Holdings Limited (“Genetron
Health” or the “Company”) (Nasdaq: GTH)
is a leading precision oncology platform company in China that
specializes in cancer molecular profiling and harnesses advanced
technologies in molecular biology and data science to transform
cancer treatment. The Company has developed a comprehensive
oncology portfolio that covers the entire spectrum of cancer
management, addressing needs and challenges from early screening,
diagnosis and treatment recommendations, as well as continuous
disease monitoring and care. Genetron Health also partners with
global biopharmaceutical companies and offers customized services
and products. For more information, please visit
ir.genetronhealth.com.
Safe Harbor Statement This
announcement contains forward-looking statements. These statements
are made under the “safe harbor” provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Statements that are not
historical facts, including statements about the Company’s beliefs
and expectations, are forward-looking statements. In some cases,
forward-looking statements can be identified by words or phrases
such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,”
“estimate,” “intend,” “plan,” “believe,” “potential,” “continue,”
“is/are likely to” or other similar expressions. Forward-looking
statements involve inherent risks and uncertainties. A number of
factors could cause actual results to differ materially from those
contained in any forward-looking statement, including but not
limited to the following: the Company’s goals and growth
strategies; the Company’s future business development, results of
operations and financial condition; relevant government policies
and regulations relating to our business and industry; the
Company’s expectations regarding demand for and market acceptance
of our diagnosis services and products, cancer early screening
services and our IVD products and our ability to expand our
customer base; the Company’s ability to obtain and maintain
regulatory approvals from the NMPA, the NCCL and have our
laboratory certified or accredited by authorities including the
CLIA and the CAP; the Company’s ability to obtain and maintain
intellectual property protections for our technologies and our
continued research and development to keep pace with technology
developments; impacts of the COVID-19 pandemic; general economic
and business condition in China; and assumptions underlying or
related to any of the foregoing. Further information regarding
these and other risks, uncertainties or factors is included in the
Company’s filings with the SEC. All information provided in this
announcement is as of the date of this announcement and based on
assumptions that the Company believes to be reasonable as of this
date, and the Company does not undertake any duty to update such
information, except as required under applicable law.
Investor Relations ContactEmail:
ir@genetronhealth.com
Media Relations ContactYanrong
Zhaoyanrong.zhao@genetronhealth.com
Genetron (NASDAQ:GTH)
Historical Stock Chart
From May 2024 to Jun 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jun 2023 to Jun 2024